Registration successful
Account activated – pending validation.
Your account has been activated successfully, but we still need to validate you as a healthcare professional. We’ll send you an email with the result of the validation process in the next [five] days.
In the meantime, you can enjoy access to all the latest news, events and resources on our website
Defining asthma control
How do patient perceptions of asthma control differ from guideline definitions?
Relvar: a considerably lower carbon footprint than MDIs1
In this day and age, it’s important to be informed as to the environmental impact of the treatments we prescribe our patients.
That’s why we’re proud to say that, compared with other asthma devices, Relvar Ellipta has one of the lowest carbon footprints.1
Annual carbon footprints (kg CO2e) for different combinations of Relvar, Seretide and Ventolin and annual footprint reduction of different actions
This graph has been independently created by GSK from the original data. The same results were first published in Janson C, et al. Thorax 2020;75:82–84.
Contribution of phases in the life cycle of different inhaler devices to their individual carbon footprint (net kg CO2e/per pack) and annual carbon footprints of each device
Discover Relvar
Need help with this product?
Footnotes
*If using on average two doses per day.
Abbreviations
CO2e, annual carbon footprint; MDI, metered dose inhaler.
References
- Janson C, et al. Thorax [1] 2020;75:82–84.
RELVAR Ellipta was created in collaboration with
Adverse events should be reported directly to the Health Products Regulatory Authority (HPRA) on their website: www.hpra.ie . Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.
Relvar is a registered trademark of the GlaxoSmithKline group of companies
PM-IE-FFV-WCNT-230009 June 2023
